MedTrace Logo

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

NCT00930982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2014-12-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find out if bacterial load in the airways can be reduced after inhalation of ciprofloxacin for 28 days.

Conditions

Interventions

DRUG

Ciprofloxacin (Cipro, BAYQ3939)

Inhalation of 32,5mg Ciprofloxacin inhaled twice a day

DRUG

Placebo

Inhalation of matching placebo twice a day

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • United States
  • Australia
  • Germany
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00930982 on ClinicalTrials.gov